250 related articles for article (PubMed ID: 32076709)
1. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.
Chemaly RF; El Haddad L; Winston DJ; Rowley SD; Mulane KM; Chandrasekar P; Avery RK; Hari P; Peggs KS; Kumar D; Nath R; Ljungman P; Mossad SB; Dadwal SS; Blanchard T; Shah DP; Jiang Y; Ariza-Heredia E
Clin Infect Dis; 2020 Dec; 71(9):2365-2374. PubMed ID: 32076709
[TBL] [Abstract][Full Text] [Related]
2. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of cytomegalovirus-specific T-cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study.
Jacobs SE; Ibrahim U; Vega AB; Lagdameo J; Callahan J; Govindarajulu U; Gitman M; Levine JE; Rana M; Keyzner A
Transpl Infect Dis; 2024 Jun; 26(3):e14290. PubMed ID: 38708941
[TBL] [Abstract][Full Text] [Related]
4. Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant.
Ariza-Heredia EJ; Winston DJ; Rowley SD; Mullane K; Chandrasekar P; Hari P; Avery RK; Peggs KS; Kumar D; Nath R; Ljungman P; Mossad SB; El Haddad L; Shah DP; Jiang Y; Khawaja F; Dadwal S; Blanchard T; Chemaly RF
Open Forum Infect Dis; 2023 Aug; 10(8):ofad386. PubMed ID: 37636519
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Refractory Cytomegalovirus Infection in the First Year after Allogeneic Hematopoietic Cell Transplantation.
Karantoni E; Zavras PD; Su Y; Fang J; Tamari R; Cho C; Perales MA; Stern A; Papanicolaou GA
Transplant Cell Ther; 2022 Jul; 28(7):403.e1-403.e7. PubMed ID: 35476955
[TBL] [Abstract][Full Text] [Related]
6. Effective CMV prophylaxis with high-dose valaciclovir in allogeneic hematopoietic stem-cell recipients at a high risk of CMV infection.
Douglas G; Yong MK; Tio SY; Chau M; Prabahran A; Sasadeusz J; Slavin M; Ritchie D; Chee L
Transpl Infect Dis; 2023 Feb; 25(1):e13994. PubMed ID: 36413495
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.
Marty FM; Winston DJ; Chemaly RF; Mullane KM; Shore TB; Papanicolaou GA; Chittick G; Brundage TM; Wilson C; Morrison ME; Foster SA; Nichols WG; Boeckh MJ;
Biol Blood Marrow Transplant; 2019 Feb; 25(2):369-381. PubMed ID: 30292744
[TBL] [Abstract][Full Text] [Related]
8. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
[TBL] [Abstract][Full Text] [Related]
9. Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
Seo E; Choi ES; Kim JH; Kim H; Koh KN; Im HJ; Lee J
PLoS One; 2021; 16(2):e0246191. PubMed ID: 33544726
[TBL] [Abstract][Full Text] [Related]
10. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
Ljungman P; Schmitt M; Marty FM; Maertens J; Chemaly RF; Kartsonis NA; Butterton JR; Wan H; Teal VL; Sarratt K; Murata Y; Leavitt RY; Badshah C
Clin Infect Dis; 2020 Apr; 70(8):1525-1533. PubMed ID: 31179485
[TBL] [Abstract][Full Text] [Related]
11. Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.
Mizuno K; Sakurai M; Kato J; Yamaguchi K; Abe R; Koda Y; Kataoka K; Mori T
Transpl Infect Dis; 2022 Dec; 24(6):e13904. PubMed ID: 35870130
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study.
Nho D; Lee R; Cho SY; Lee DG; Kim EJ; Park S; Lee SE; Cho BS; Kim YJ; Lee S; Kim HJ
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766290
[TBL] [Abstract][Full Text] [Related]
13. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
[TBL] [Abstract][Full Text] [Related]
14. Update on prevention of cytomegalovirus in hematopoietic cell transplantation.
Dadwal SS
Curr Opin Infect Dis; 2019 Feb; 32(1):63-68. PubMed ID: 30543548
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance.
Lindsay J; Othman J; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Pergam SA; Liu C; Slavin MA; Greenwood M
Transpl Infect Dis; 2021 Jun; 23(3):e13548. PubMed ID: 33342000
[TBL] [Abstract][Full Text] [Related]
16. Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial.
Jarque M; Crespo E; Melilli E; Gutiérrez A; Moreso F; Guirado L; Revuelta I; Montero N; Torras J; Riera L; Meneghini M; Taco O; Manonelles A; Paul J; Seron D; Facundo C; Cruzado JM; Gil Vernet S; Grinyó JM; Bestard O
Clin Infect Dis; 2020 Dec; 71(9):2375-2385. PubMed ID: 32076718
[TBL] [Abstract][Full Text] [Related]
17. High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience.
Kabut T; Weinbergerová B; Folber F; Lengerová M; Mayer J
Bone Marrow Transplant; 2023 Nov; 58(11):1229-1236. PubMed ID: 37612466
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.
Marty FM; Ljungman PT; Chemaly RF; Wan H; Teal VL; Butterton JR; Yeh WW; Leavitt RY; Badshah CS
Am J Transplant; 2020 Jun; 20(6):1703-1711. PubMed ID: 31883426
[TBL] [Abstract][Full Text] [Related]
19. Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation.
Páez-Vega A; Cantisán S; Agüera ML; Suñer M; Facundo C; Yuste JR; Fernández-Ruiz M; Montejo M; Redondo-Pachón D; López-Oliva MO; Fernández-Rodríguez A; Fariñas MC; Hernández D; Len O; Muñoz P; Valle-Arroyo J; Rodelo-Haad C; Cordero E; Torre-Cisneros J
J Infect Dis; 2021 Apr; 223(7):1205-1213. PubMed ID: 32779713
[TBL] [Abstract][Full Text] [Related]
20. Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.
Nesher L; Shah DP; Ariza-Heredia EJ; Azzi JM; Siddiqui HK; Ghantoji SS; Marsh LY; Michailidis L; Makedonas G; Rezvani K; Shpall EJ; Chemaly RF
J Infect Dis; 2016 Jun; 213(11):1701-7. PubMed ID: 26908740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]